Literature DB >> 11559893

Management of pediatric postrenal transplantation infections.

V R Dharnidharka1, W E Harmon.   

Abstract

Infections are the leading cause of hospitalization and death after renal transplantation in children. Various agents are implicated in posttransplantation infections. Viral infections due to the cytomegalovirus and Epstein-Barr virus have assumed greater importance as other infections such as pneumocystis pneumonia have come under control. Multiple factors contribute to the difficulty in the prevention, diagnosis, and treatment of pediatric postrenal transplantation infections. Prevention of infections by adequate preparation before transplantation and the use of chemoprophylaxis should be made a priority. An aggressive approach to diagnosis is required when investigating fever in children. It is hoped that the use of more specific immunosuppressive agents that block only the alloactivated T cells and leave the rest of the immune response intact may result in a reduction in the number and frequency of infections. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559893     DOI: 10.1053/snep.2001.24947

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  4 in total

1.  Renal transplantation: the present and the future.

Authors:  Vikas R Dharnidharka
Journal:  Indian J Pediatr       Date:  2005-09       Impact factor: 1.967

Review 2.  Monitoring and managing viral infections in pediatric renal transplant recipients.

Authors:  Patrizia Comoli; Fabrizio Ginevri
Journal:  Pediatr Nephrol       Date:  2011-02-26       Impact factor: 3.714

Review 3.  Post-transplant lymphoproliferative disease: association with induction therapy?

Authors:  Vikas R Dharnidharka
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Post-transplant lymphoproliferative disease.

Authors:  Vikas R Dharnidharka; Carlos E Araya
Journal:  Pediatr Nephrol       Date:  2007-09-19       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.